ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Neoplasm Metastasis

Breast Cancer trials near Durham, NC, USA:

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).The Following drugs will be ...

Active, not recruiting
Inflammatory Breast Cancer (IBC)
Drug: Paclitaxel
Drug: Cyclophosphamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Durham, North Carolina, United States and 3 other locations

This research study is for patients with metastatic breast cancer.* Metastatic means that the cancer has spread beyond the ...

Active, not recruiting
Somatic Mutation Breast Cancer (BRCA1)
Somatic Mutation Breast Cancer (BRCA2)
Drug: Olaparib

Phase 2

Beth Israel Lahey Health
Beth Israel Lahey Health

Durham, North Carolina, United States and 19 other locations

triple negative (TN) or hormone receptor positive/HER2-negative breast cancer.The names of the study interventions involved in this...

Enrolling
Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
Triple Negative Breast Cancer
Drug: Paclitaxel
Drug: Carboplatin

Phase 2

Laura M. Spring, MD

Durham, North Carolina, United States and 9 other locations

therapy as a treatment after surgery for hormone receptor positive breast cancer.The study drugs involved in this study are:* A com...

Enrolling
Breast Cancer
Hormone Receptor Positive Breast Cancer
Drug: ADJUVANT ENDOCRINE THERAPY
Combination Product: Pertuzumab+TRASTUZUMAB

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Chapel Hill, North Carolina, United States and 27 other locations

This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which...

Active, not recruiting
Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Chapel Hill, North Carolina, United States and 9 other locations

This research study is studying a combination of drugs as a possible treatment for breast cancer.The drugs involved in this study a...

Active, not recruiting
Breast Cancer
Drug: Avelumab
Drug: Trastuzumab

Phase 2

Adrienne G. Waks

Durham, North Carolina, United States and 16 other locations

to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...

Active, not recruiting
Estrogen Receptor Positive Breast Cancer
HER-2 Positive Breast Cancer
Drug: palbociclib
Drug: trastuzumab

Phase 3

Alliance Foundation Trials

Durham, North Carolina, United States and 117 other locations

In this research study we are studying the effects of the combination of lapatinib plus Herceptin in subjects with breast cancer th...

Active, not recruiting
Breast Cancer
Drug: Lapatinib
Drug: Herceptin

Phase 2

Nancy Lin, MD

Chapel Hill, North Carolina, United States and 8 other locations

together. A side effect is anything a drug does besides treating cancer.Participants in this trial have HER2-positive (HER2+) breast...

Active, not recruiting
HER2 Positive Breast Cancer
Drug: trastuzumab deruxtecan
Drug: tucatinib

Phase 2

Seagen
Seagen

Chapel Hill, North Carolina, United States and 32 other locations

postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have diseas...

Active, not recruiting
Locally Advanced or Metastatic Breast Cancer
Drug: Lasofoxifene
Drug: Fulvestrant

Phase 2

Sermonix Pharmaceuticals

Durham, North Carolina, United States and 50 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems